Track topics on Twitter Track topics that are important to you
Here are the most relevant search results for "BioPharma-Reporter" found in our extensive news archives from over 250 global news sources.
In addition to our news stories we have dozens of PubMed Articles about BioPharma-Reporter for you to read. Along with our medical data and news we also list BioPharma-Reporter Clinical Trials, which are updated daily. BioPortfolio also has a large database of BioPharma-Reporter Companies for you to search.
The Nordic life science cluster aspires to become the most prominent in northern Europe, says Medicon Valley Alliance executive.
GE Healthcare will manufacture single-use consumables for bioprocessing through a collaboration with Wego.
The company will launch Udenyca onto the US market on January 3, 2019, to compete with Amgenâs originator product and Mylanâs rival biosimilar.
Denmark played host to its first BIO Europe this week, welcoming 4,500 attendees from across the globe â including growing numbers from China and South Korea.
The company will construct two facilities in Japan and relocate its regenerative medicine facility in the US.
As an increasing number of biosimilar developers target the European market, lesser-known firms may explore alternative commercialisation strategies, says Iqvia executive.
After the business was asked by the US FDA to provide more data to secure an approval for its biosimilar, Sandoz decided not to pursue its regulatory filing any further.
Ncardia and Horizon Discovery have partnered to provide custom, genetically- modified and differentiated human cells for drug discovery and preclinical models.
In Europe, biosimilar rivals have undercut Humiraâs list price from 10% to 80%, says AbbVie CEO.
With cell and gene therapies developing at a rapid pace, it leaves significant questions as to how manufacturing processes are keeping up.
The Danish drugmaker announced that job losses at the company will number 1,300 before the end of the year, with the majority of those already having left their roles.
A study published by graduate students at MIT showed that a synthetic mRNA-based âprogramming languageâ can control protein expression in gene therapy.
The US FDA approval, coupled with a Humira licensing agreement, will see Sandozâ biosimilar enter the market as of September 30, 2023.
In a significant move at the larger end of the biopharma world, AstraZenecaâs global VP of cardiovascular, renal and metabolism made the move to Novo Nordisk to head up its biopharm unit.
Construction has started at WuXi Biologicsâ eighth drug substance manufacturing facility, which CEO Chris Chen says will enable the CDMO to âdevelop and manufacture biologics more cost effectivelyâ.
After a three-year partnership, Lonza pulled the trigger on acquiring a controlling stake of Octane Biotech and their jointly developed Cocoon system.
The US FDA has rejected Regeneron Pharmaceuticalsâ prior-approval supplement for Elyea pre-filled syringe, requesting additional clinical data and manufacturing information.
Johnson & Johnson has unveiled a vaccine facility in Leiden, the Netherlands, which will focus on R&D, technological development, and large-scale production of vaccines for late-stage clinical trials.
Within days of Samsung Bioepis sending its Soliris candidate to the clinic, the firm details its development process, novel biologics ambitions, and plans to become âthe single dominant player in biosimilarsâ.
Shire has filed a US FDA submission to manufacture plasma-volume replacement therapy, Flexbumin, at its new plant in Stanton Springs, Georgia.
MSD announced that the EMAâs CHMP has adopted a positive opinion recommending approval of Keytruda as an adjuvant therapy for the treatment of patients with melanoma.
The first MabThera biosimilar is expected to enter the US market in the first half of 2019, followed by Herceptin and Avastin versions in the second half of the year, says CEO.
The company is considering an expansion beyond biosimilars into novel biologics development, says CEO TH Kim.
Avid continues its transition to a fully-fledged CDMO by transforming its process development capabilities with new lab space.
MilliporeSigma collaborated with GylcoBac to provide an Sf-9 insect cell line for vaccine and gene therapy development.